MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS.
The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.